Background-The Coronary Psychosocial Evaluation Studies (COPES) trial demonstrated promising results for enhanced depression treatment to reduce cardiovascular risk of patients with acute coronary syndrome and comorbid depression, but the long-term effectiveness of this intervention is unclear.
Introduction
Depression is associated with increased risk for death and major adverse cardiac events in patients with coronary heart disease (1) . Prior trials of brief depression treatment have failed to demonstrate long-term benefits on cardiovascular outcomes (2, 3) . In the Coronary Psychosocial Evaluation Studies (COPES) randomized controlled trial, we have previously reported that patient-preference based, enhanced depression treatment compared to usual care in patients with acute coronary syndromes may reduce the risk of death or major adverse cardiac events during the 6-months treatment period (4) . To address whether this treatment effect was durable when active treatment ended, we examined cardiac events and mortality in the COPES trial through an additional 12 months of observational follow-up after the end of the 6-month treatment period.
Methods
As previously described (4), 157 patients with a score of ≥10 on the Beck Depression Inventory (5) within 1 week of acute coronary syndrome hospitalization and again at 3-month follow-up were recruited from January 1, 2005, through February 29, 2008. Patients were randomized to either usual care or to enhanced depression treatment involving stepped, patient-preference driven care with problem-solving therapy, pharmacotherapy, or both. Demographic data and medical history were collected at index hospitalization. During the 6-month treatment period and for an additional 12 months after treatment ended, hospitalization information was collected for all patients, and hospital systems were surveyed actively for hospitalizations of trial participants. Hospitalization records were adjudicated in a blinded fashion by two cardiologists to determine occurrences of major adverse cardiac events, defined as nonfatal myocardial infarction or hospitalization for unstable angina; a third cardiologist resolved disagreements. The National Death Index was searched to confirm reported deaths and to determine vital status of those who could not be contacted.
For this analysis, we constructed Cox proportional hazards models to estimate the effect of enhanced depression treatment on time-to-death or first major adverse cardiac event, adjusted for age, sex, Global Registry of Acute Coronary Events risk score (6) , and left ventricular ejection fraction. Because a formal significance test based on scaled and unscaled Schoenfeld residuals confirmed that the treatment effect differed between the treatment and the observational follow-up time periods (p=0.008),(7) treatment assignment was entered in the model as a time-varying covariate, with separate estimates reported for the effect of enhanced depression treatment during the 6-month intervention period and for the 12-month subsequent observational follow-up.
Results
Of the 157 participants with persistent depressive symptoms 3 months after an index acute coronary syndrome hospitalization, 80 were randomized to enhanced depression treatment and 77 were randomized to usual care (Figure 1) , as has been reported previously.(4) There was no significant difference between the two groups with regards to age, sex, race, ethnicity, education level, marital status, baseline Beck Depression Inventory score, Global Registry of Acute Coronary Events risk score, revascularization status during index hospitalization, or left ventricular ejection fraction ( Table 1) .
The median follow-up period was 11.8 months after treatment ended. During the 6-month intervention period, 11 (14%) participants in the usual care arm experienced the composite outcome of death or hospitalization for myocardial infarction / unstable angina, including one participant whose death was not identified in our previously published analysis. 
Discussion
During the observational follow-up of the COPES randomized controlled trial, we found that the original finding of a reduced risk of death or hospitalization for myocardial infarction / unstable angina during the 6-month treatment period did not persist after treatment ended. Furthermore, there was a significant time-treatment interaction in the opposite direction, suggesting that there may have been a "catch-up" in cardiovascular events after the intervention ended. To our knowledge, this is the first report of a "catch-up" phenomenon concerning cardiac events after the end of depression treatment, with implications for future trials of depression management in patients with coronary heart disease.
Recent trials of novel depression interventions in this patient population have mainly examined the effect of interventions during the period in which depression treatment is offered. In a trial of 214 participants from 14 primary care clinics, Katon and colleagues showed that a stepped, patient-preference based intervention led to improvements in both depressive symptoms and management of coronary heart disease, compared to usual care, during the 12-months treatment period. (8) Similarly, Blumenthal and colleagues recently reported that for patients with coronary heart disease and elevated depressive symptoms, a 4-month structured exercise intervention improved heart rate variability, a marker of cardiac risk, as compared to those receiving sertraline or placebo, at the end of the 4-month period. (9) However, as the current findings suggest, the extent to which the benefits reported in these studies will persist after the completion of the interventions tested cannot be assumed. Future trials targeting depression in coronary heart disease patients may need to consider longer treatment duration, as well as evaluate the benefits and costs of ongoing symptom monitoring and "booster" treatments.
There are several potential mechanisms for the "catch up" phenomenon in cardiac risk that we observed. Depression is associated with biological processes, such as inflammation and endothelial dysfunction, (10) (11) (12) and behavioral processes, such as smoking and physical inactivity, (13) that are known to contribute to worse outcomes after hospitalizations for acute coronary syndromes. A 6-month course of depression treatment may not be sufficient to permanently affect these pathways, or may be too brief to prevent a rebound in these processes after treatment discontinuation. Alternatively, since depression is a chronic illness defined by a remitting-relapsing course, it is possible that patients with untreated or undertreated relapses in depressive symptoms post-intervention may have particularly high cardiovascular risk during those time-periods of symptom rebound. A better understanding of the complex interactions between depression treatment, depressive symptoms, and the biological and behavioral mediators of cardiac risk in patients with depression after an acute coronary syndrome event is needed to better understand the "catch-up" phenomenon for cardiac risk that we observed.
The current findings have several limitations, including the small study size and the post-hoc nature of the analyses. Given the small number of events, it is possible that chance finding or regression to the mean could explain the "catch-up" phenomenon we observed. In addition, differential loss to follow-up due to a healthy survivor effect cannot be ruled out. It is also unknown whether participants undertook cardiac rehabilitation or other activities that could affect quality of life and cardiac risk during the treatment and follow-up time periods. Furthermore, it is unknown what types of depression treatment, if any, were received by participants during the observational follow-up. These findings are thus hypothesisgenerating and require replication. Nonetheless, our study raises the possibility that the treatment of depression in patients with acute coronary syndromes may need to be of longer duration to maintain the cardiac benefits observed during treatment. Future research is needed to confirm our findings, to determine the optimal duration of initial depression treatment in this patient population, and to identify treatment approaches that will deliver durable results. Title: Survival free from death or hospitalization for myocardial infarction or unstable angina, by treatment assignment.
